ClinicalTrials.gg

Program

Immunoglobulins, Intravenous

Also written as “NPB-01”, “TAK-881” and “IVIG”.

Its studies are mostly in Primary Immunodeficiency Diseases · Purpura, Thrombocytopenic, Idiopathic · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Immunologic Deficiency Syndromes · Myasthenia Gravis, led by 18 companies.

Furthest: phase 4, since Apr 12, 201783 company-led studies, 14 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda203 open or runningphase 4since Apr 12, 2017Sep 8, 2005May 16, 2028phase 3 · NCT06076642
Grifols172 open or runningphase 4since Oct 24, 2011Sep 13, 2005Dec 31, 2027phase 3 · NCT07540221
Nihon Pharmaceutical80 open or runningphase 3since Jul 27, 2011Dec 11, 2008none ahead
Octapharma61 open or runningphase 3since Nov 11, 2009Nov 11, 2009Nov 2026phase 3 · NCT04640142
CSL51 open or runningphase 3since Oct 12, 2011Oct 12, 2011May 6, 2029phase 2 · NCT07048262
Kedrion53 open or runningphase 3since Apr 16, 2012Apr 16, 2012Dec 2026phase 3 · NCT07059000
Japan Blood Products Organization40 open or runningphase 3since Jun 8, 2006Jun 8, 2006none ahead
GC Biopharma31 open or runningphase 3since Jul 26, 2011Jul 26, 2011none ahead
Prothya Biosolutions30 open or runningphase 4since Aug 29, 2007Aug 29, 2007none ahead
Azidus Brasil22 open or runningphase 3since Sep 19, 2023Sep 19, 2023Sep 2028phase 3 · NCT06150833
benesis-corporation20 open or runningphase 3since Jul 3, 2006Jul 3, 2006none ahead
biopharma-plasma-llc20 open or runningphase 3since Jul 15, 2020Jul 15, 2020none ahead
AstraZeneca10 open or runningphase 4since Aug 23, 2023Aug 23, 2023none ahead
dobri-kiprov11 open or runningphase 3since Jul 17, 2024Jul 17, 2024none ahead
evolve-biologics10 open or runningphase 3since Jul 21, 2017Jul 21, 2017none ahead
gammacan10 open or runningphase 2since Feb 19, 2006Feb 19, 2006none ahead
immunoe-research-centers10 open or runningphase 4since Nov 14, 2017Nov 14, 2017none ahead
isaac-melamed10 open or runningphase 4since Jul 21, 2014Jul 21, 2014none ahead

Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire, Parexel, Premier Research Group and TFS Trial Form Support.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 47 studies since Oct 6, 2010.

  1. Sep 19, 2023Azidus Brasil’s first study: phase 3 study in Primary Immunodeficiency DiseasesNew to Azidus BrasilAzidus Brasil · NCT06089122 · 50 planned
  2. Oct 4, 2023Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT06076642 · 53 enrolled · United States, Czechia, Denmark and more
  3. Nov 21, 2023Phase 3 study in Primary Immunodeficiency DiseasesAzidus Brasil · NCT06150833 · 50 planned
  4. Jul 17, 2024dobri-kiprov’s first study: phase 3 study in AgingNew to dobri-kiprovdobri-kiprov · NCT06534450 · 40 enrolled · United States
  5. Dec 19, 2024Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingTakeda · NCT06747351 · 59 planned · United States, Argentina, Czechia and more
  6. Mar 20, 2025Phase 1 study in Healthy VolunteersTakeda · NCT06895967 · 30 enrolled · United States
  7. Apr 11, 2025Phase 1 study in Healthy VolunteersTakeda · NCT06935266 · 64 enrolled · United States
  8. May 13, 2025Phase 3 study in Multiple MyelomaTakeda · NCT06980480 · 183 planned · United States, Australia, Austria and more
  9. Jun 18, 2025Phase 3 study in Purpura, Thrombocytopenic, IdiopathicKedrion · NCT07059000 · 40 planned · United States, Czechia, Germany and more
  10. Jun 24, 2025Phase 2 study in InflammationCSL · NCT07048262 · 180 planned · Australia, Japan
  11. Apr 9, 20262 phase 3 studiesGrifols · NCT07540221, NCT07582432
  12. Apr 17, 2026Phase 3 study in Stiff-Person SyndromeKedrion · NCT07552987 · 38 planned
  13. Oct 19, 2026Primary completion moved from 2028-02-28 to 2029-05-06Date moved laterphase 2 · +14 months · NCT07048262
  14. Nov 9, 2026Primary completion moved from 2026-09 to 2026-11Date moved laterphase 3 · +2 months · NCT04640142

Ahead

  1. Nov 2026Primary completion: phase 3 study in Primary Immunodeficiency DiseasesOctapharma · NCT04640142
  2. Dec 2026Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicKedrion · NCT07059000
  3. Dec 2026Primary completion: phase 3 study in Primary Immunodeficiency DiseasesKedrion · NCT04944979
  4. Dec 31, 2027Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingGrifols · NCT07540221

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The newest 60 of 83 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07552987Stiff-Person Syndrome3Not yet recruitingKedrionJan 202838
NCT07582432Leukemia, Lymphocytic, Chronic, B-Cell · United States3RecruitingGrifolsAug 31, 202849
NCT07540221Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Czechia, Poland and more3RecruitingGrifolsDec 31, 202740
NCT07048262Inflammation · Australia, Japan2RecruitingCSLMay 6, 2029180
NCT07059000Purpura, Thrombocytopenic, Idiopathic · United States, Czechia, Germany and more3RecruitingKedrionDec 202640
NCT06980480Multiple Myeloma · United States, Australia, Austria and more3RecruitingTakedaSep 11, 2028183
NCT06935266Healthy Volunteers · United States1CompletedTakedaSep 27, 202564
NCT06895967Healthy Volunteers · United States1CompletedTakedaJul 24, 202530
NCT06747351Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Czechia and more3RecruitingTakedaJun 25, 202859
NCT06534450Aging · United States3Active, not recruitingdobri-kiprovNov 30, 202340
NCT06150833Primary Immunodeficiency Diseases3Not yet recruitingAzidus BrasilSep 202850
NCT06076642Primary Immunodeficiency Diseases · United States, Czechia, Denmark and more3Active, not recruitingTakedaMay 16, 202853
NCT06089122Primary Immunodeficiency Diseases3Not yet recruitingAzidus BrasilJan 8, 202550
NCT06015750Hypophosphatasia4WithdrawnAstraZenecaMar 13, 20300
NCT05755035Primary Immunodeficiency Diseases · United States, Czechia, Denmark and more3CompletedTakedaJan 20, 202665
NCT05422365Purpura, Thrombocytopenic, Idiopathic · Ukraine3Completedbiopharma-plasma-llcDec 14, 202332
NCT05177939Autoimmune Diseases of the Nervous System · Japan3UNKNOWNNihon PharmaceuticalMay 31, 202440
NCT05059977Healthy Volunteers · United States1CompletedTakedaApr 12, 202224
NCT04944979Primary Immunodeficiency Diseases · United States, Hungary, Italy and more3Active, not recruitingKedrionDec 202630
NCT04643587Noncystic Fibrosis Bronchiectasis (NCFB) · Germany, United Kingdom1CompletedCSLMar 12, 202364
NCT04640142Primary Immunodeficiency Diseases · United States, Germany, Hungary and more3Active, not recruitingOctapharmaNov 202650
NCT04565015Primary Immunodeficiency Diseases · United States, Bosnia and Herzegovina, Serbia3Active, not recruitingGC BiopharmaMay 202624
NCT04500067COVID-19 · Ukraine3Completedbiopharma-plasma-llcSep 15, 202076
NCT04432324COVID-19 · Spain2CompletedGrifolsMar 3, 2021100
NCT04346108Primary Immunodeficiency Diseases · Japan3CompletedTakedaDec 22, 202117
NCT04044690Dermatomyositis · United States, Argentina, Belgium and more3TerminatedCSLDec 2, 2024134
NCT03961009Primary Immunodeficiency Diseases · United States3CompletedKedrionDec 21, 202047
NCT03351933Anti-Hepatitis A Antibody Levels in Heathy Subjects · United States4CompletedGrifolsApr 27, 201828
NCT03348618Pediatric acute-onset neuropsychiatric syndrome · United States4UNKNOWNimmunoe-research-centersNov 201921
NCT03238079Primary Immunodeficiency Diseases · United States, Canada3Completedevolve-biologicsAug 25, 202063
NCT03116347Primary Immunodeficiency Diseases · Czechia, Denmark, France and more4CompletedTakedaJan 15, 202142
NCT02783482Immunologic Deficiency Syndromes · United States, Canada3CompletedGC BiopharmaJul 201949
NCT02638207Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy · Bulgaria, Canada, Czechia and more3CompletedOctapharmaSep 5, 2019142
NCT02473965Myasthenia Gravis · United States, Belgium, Canada and more2CompletedGrifolsFeb 201960
NCT02473952Myasthenia Gravis · United States, Belgium, Canada and more2CompletedGrifolsJan 201862
NCT02413580Myasthenia Gravis Exacerbations · Argentina, Belgium, Canada and more3CompletedGrifolsApr 201849
NCT02342184Guillain-Barre Syndrome · Japan3CompletedJapan Blood Products OrganizationSep 201521
NCT02221271Guillain-Barre Syndrome · Japan3CompletedNihon PharmaceuticalAug 201522
NCT02199925Autistic Disorder · United States4UNKNOWNisaac-melamedApr 201530
NCT02184741Abortion, Habitual · Japan3CompletedJapan Blood Products OrganizationMay 202099
NCT02176863Postpoliomyelitis Syndrome · United States, Canada, Czechia and more3TerminatedGrifolsNov 24, 2022191
NCT02032095Kidney Failure, Chronic · Japan3CompletedJapan Blood Products OrganizationSep 201517
NCT01985373Primary Immunodeficiency Diseases · Netherlands3CompletedProthya BiosolutionsMar 201523
NCT01845584Neuromyelitis Optica · Japan2CompletedNihon PharmaceuticalAug 20157
NCT01827072Multifocal Motor Neuropathy · Japan3CompletedNihon PharmaceuticalJun 201513
NCT01824251Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Japan3CompletedNihon PharmaceuticalSep 201549
NCT01736579Alzheimer´s Disease · United States3TerminatedTakedaJun 4, 20136
NCT01696500Stevens-Johnson Syndrome · Japan3CompletedNihon PharmaceuticalJun 201410
NCT01581593Primary Immunodeficiency Diseases · United States, Canada3CompletedKedrionAug 27, 201445
NCT01524887Alzheimer´s Disease · United States, Australia, Belgium and more3TerminatedTakedaJul 16, 2013508
NCT01465958Primary Immunodeficiency Diseases · United States4CompletedGrifolsOct 201312
NCT01461018Primary Immunodeficiency Diseases · Japan3CompletedCSLJul 201422
NCT01458171Primary Immunodeficiency Diseases · Japan3CompletedCSLFeb 201223
NCT01412385Primary Immunodeficiency Diseases · Austria, Germany, Hungary and more3CompletedTakedaMay 13, 201455
NCT01408550Pemphigoid, Bullous · Japan3CompletedNihon PharmaceuticalSep 201356
NCT01406470Immunologic Deficiency Syndromes · United States, Canada3CompletedGC BiopharmaJul 201345
NCT01349790Purpura, Thrombocytopenic, Idiopathic · Germany3CompletedOctapharmaJul 201340
NCT01313507Primary Immunodeficiency Diseases · United States3CompletedOctapharmaSep 201221
NCT01218438Primary Immunodeficiency Diseases · United States, Canada3CompletedTakedaMar 13, 201586
NCT01225276Polyradiculoneuropathy, Chronic Inflammatory Demyelinating3TerminatedOctapharmaOct 20122

How it is read

Names in the registry

  • “NPB-01”, 7 entries
  • “TAK-881”, 6 entries
  • “IVIG”, 6 entries
  • “Kedrion IVIG 10%”, 4 entries
  • “GB-0998”, 4 entries

Codes read as this program: TAK881, GC5107, GB0998.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.